0 Items
Select Page

Cytomegalovirus

Cytomegalovirus (CMV) is a ubiquitous virus that can infect almost anyone. Most people are unaware that they have CMV, because it rarely causes problems in healthy people. But for pregnant women or those with weakened immune system, CMV is cause for concern. A woman who develops an active CMV infection during pregnancy may pass the virus to her baby, which in a small percentage of cases can cause congenital birth defects. For people with compromised immunity, especially due to organ transplantation, CMV infection can be fatal.

At The Native Antigen Company, we offer an extensive range of reagents for CMV research. These include preparations of native purified virus, mammalian-expressed recombinant proteins and a panel of related antibodies.

Cytomegalovirus Background

Cytomegalovirus (CMV, or human betaherpesvirus 5) is a human-specific double-stranded DNA virus, belonging to the Herpesviridae family. CMV is ubiquitous and CMV infection is globally widespread. The virus is transmitted through direct contact with infected bodily fluids, or though contact with virus-infected transplant and transfusion material. CMV can also be transferred in utero from mother to foetus during pregnancy resulting in congenital CMV (cCMV) infection of new-borns. In healthy adults and children, CMV infection is self-limiting with most cases being asymptomatic or presenting with mild, non-specific flu-like or mononucleosis-like symptoms. However, CMV can cause clinical disease in all organs of immunocompromised patients and congenital complications in babies born to infected mothers. Congenital CMV infection represents a significant health risk to new-borns, as children with CMV infection may experience physical disability, learning difficulties, visual impairment and deafness. Currently, there is no licensed vaccine to prevent CMV infection. Therefore, attempts to reduce the risk of cCMV infection by improving awareness, behaviour, screening, diagnosis and the treatment of symptomatic cases are the most immediate means of mitigating the health burden caused by cCMV (CDC).

References

  1. Centers for Disease Control and Prevention: Cytomegalovirus (CMV) and congenital CMV infection.

Cytomegalovirus Antigens

The Native Antigen Company have developed a range of CMV antigens that are suitable for both IVD assay development and vaccine R&D studies. These antigens include preparations from native virus and highly purified recombinant proteins, expressed in mammalian cells.

Our recombinant antigens include the two key vaccine candidates for CMV: CMV pentamer protein and glycoprotein B.

Cytomegalovirus Antibodies

Our CMV-specific antibodies have been fully validated using antigens produced by The Native Antigen Company. The range includes CMV-specific antibodies against glycoprotein B and CMV pentamer. Sheep anti-CMV pentamer antibody has been raised against recombinant CMV gH pentameric complex, expressed in mammalian cells, and has been shown to react with each of the components of the pentamer in Western blotting analysis. Mouse anti-CMV glycoprotein B antibody clone HCMV37, recognises and binds a neutralising epitope on CMV glycoprotein B. It has been tested on recombinant CMV glycoprotein B, produced by the Native Antigen Company and has shown to bind effectively in direct ELISA.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Gonorrhea: What’s Currently in the Clinical Pipeline?

This article was written by our friends at Infectious Diseases Hub, a free-to-access website that aims to deliver up-to-date, essential research and information on all aspects of microbiology, virology, mycology and parasitology – from bench to bedside....

Novel Coronavirus Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

The Why and How of Protein Conjugation

In this blog, Lead Assay Development Scientist, Toni Ertl discusses the basics of protein conjugation and introduces our new range of conjugation kits for the labelling of antigens and antibodies.Detecting Proteins If you’re trying to detect or measure the presence...

Going Viral: Why We Need New Diagnostics For a Safe and Effective Dengue Vaccine

This article is taken from European Biopharmaceutical Review January 2020, pages 44-46. © Samedan Ltd.The Dengue VirusDengue is the world’s most prevalent and consequential arboviral disease. Current estimates indicate that as many as 390 million dengue infections...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

7 + 1 =

Live Customer Feedback

Join our mailing list

* indicates required